<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The diagnosis of <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e>, a condition characterised by mild <z:hpo ids='HP_0000952'>jaundice</z:hpo> related to <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0008282'>unconjugated hyperbilirubinemia</z:hpo>, is often presumptive and the pathogenesis is incompletely understood </plain></SENT>
<SENT sid="1" pm="."><plain>It would be of interest to develop an immunohistochemical staining method to confirm a diagnosis of <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>To this end liver tissues from ten patients with a presumed diagnosis of <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> and six <z:mpath ids='MPATH_458'>normal</z:mpath> controls were examined by immunohistochemistry with polyclonal antibodies raised to <z:chebi fb="15" ids="17659">UDP</z:chebi>-glucuronosyltransferase (UGT) </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> subjects had <z:mpath ids='MPATH_458'>normal</z:mpath> liver biopsies by hemotoxylin and eosin staining </plain></SENT>
<SENT sid="4" pm="."><plain>In <z:mpath ids='MPATH_458'>normal</z:mpath> human liver specific staining for UGT was seen diffusely in <z:hpo ids='HP_0000001'>all</z:hpo> hepatocytes of the hepatic lobule with zone 3 accentuation </plain></SENT>
<SENT sid="5" pm="."><plain>There was a reduction of immunostaining throughout the hepatic lobule in <z:hpo ids='HP_0000001'>all</z:hpo> specimens from patients with <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> and faint residual staining was seen in zone 3 </plain></SENT>
<SENT sid="6" pm="."><plain>This thus proved a useful method to confirm a clinical diagnosis of <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Raising monospecific antibodies to UGT may give an insight into polypmorphisms of phase II drug metabolism </plain></SENT>
<SENT sid="8" pm="."><plain>Bosma et al.* have recently provided evidence from in vitro studies that subjects with <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> have a putative defect in the promoter region of the gene encoding <z:chebi fb="15" ids="17659">UDP</z:chebi>-glucuronosyltransferase 1, resulting in reduced transcription </plain></SENT>
<SENT sid="9" pm="."><plain>These studies have yet to be confirmed from human biopsy specimens and the possibility of second mutations in intronic sequences affecting the stability of <z:chebi fb="15" ids="17659">UDP</z:chebi>-glucuronosyltransferase 1 m <z:chebi fb="40" ids="33697">RNA</z:chebi> are being explored. *Bosma PJ, Chowdhury JR, Bakker C et al </plain></SENT>
<SENT sid="10" pm="."><plain>The genetic basis of the reduced expression of <z:chebi fb="0" ids="16990">bilirubin</z:chebi> <z:chebi fb="15" ids="17659">UDP</z:chebi>-glucuronosyltransferase 1 in <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>N Engl J Med 1995; 333: 1171-5 </plain></SENT>
</text></document>